To include your compound in the COVID-19 Resource Center, submit it here.

LRRK2 looming larger

University of Pittsburgh team links LRRK2 activity to idiopathic PD

Researchers from the University of Pittsburgh have identified a link between LRRK2 activity and idiopathic forms of Parkinson’s disease, further broadening the potential patient population for LRRK2 inhibitors in development, including two clinical compounds from Denali Therapeutics Inc. (NASDAQ: DNLI).

Multiple gain-of-function mutations in leucine-rich repeat kinase 2 (LRRK2) have been implicated in autosomal dominant forms of

Read the full 577 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers